Sexual risk behavior in HIV-infected injection drug users

Clinical Infectious Diseases

Volumn 38, Issue 8, 2004, Pages 1175-1177

  Battegay, Manuel ^a   Bucher, Heiner C ^a,b   Vernazza, Pietro ^c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIAMORPHINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CAREGIVER; CONTROLLED STUDY; DRUG ABUSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; NOTE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SAFE SEX; SEROCONVERSION; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; VIRUS TRANSMISSION; ADULT; DISEASE TRANSMISSION; DRUG EFFECT; FEMALE; HIGH RISK BEHAVIOR; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; PSYCHOLOGICAL ASPECT; SUBSTANCE ABUSE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; NEEDLE SHARING; RISK-TAKING; SAFE SEX; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 2342525362     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/383069     Document Type: Note

References (13)

1. Khalsa JH, Francis H, Mazin R. Bloodborne and sexually transmitted infections in drug abusers in the United States, Latin America, the Caribbean, and Spain. Clin Infect Dis 2003; 37(Suppl 5):S331-7.
2. Sosa-Estani S, Rossi D, Weissenbacher M. Epidemiology of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome in injection drug users in Argentina: high seroprevalence of HIV infection. Clin Infect Dis 2003; 37(Suppl 5):S338-42.
3. Bassetti S, Battegay M, Furrer H, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 1999; 21:114-9.
4. Tun W, Gange SJ, Vlahov D, Strathdee SA, Celentano DD. Increase in sexual risk behavior associated with immunologic response to highly active antiretroviral therapy among HIV-infected injection drug users. Clin Infect Dis 2004; 38:1167-74 (in this issue).
5. Bouhnik AD, Moatti JP, Vlahov D, Gallais H, Dellamonica P, Obadia Y. Highly active anti-retroviral treatment does not increase sexual risk behaviour among French HIV infected injecting drug users. J Epidemiol Community Health 2002; 56:349-53.
6. Wolf K, Young J, Rickenbach M, et al. Prevalence of unsafe sexual behavior among HIV-infected individuals: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2003; 33:494-9.
7. Vlahov D, Safaien M, Lai S, et al. Sexual and drug risk-related behaviours after initiating highly active antiretroviral therapy among injection drug users. AIDS 2001; 15:2311-6.
8. Panozzo L, Battegay M, Friedl A, Vernazza PL. High risk behaviour and fertility desires among heterosexual HIV-positive patients with a serodiscordant partner: two challenging issues. Swiss Med Wkly 2003; 133:124-7.
9. Latka M. Drug-using women need comprehensive sexual risk reduction interventions. Clin Infect Dis 2003; 37(Suppl 5):S445-50.
10. Muga R, Sanvisens A, Egea JM, Tor J, Rey-Joly C. Trends in human immunodeficiency virus infection among drug users in a detoxification unit. Clin Infect Dis 2003; 37(Suppl 5):S404-9.
11. Astemborski J, Vlahov D, Warren D, Solomon L, Nelson KE. The trading of sex for drugs or money and HIV seropositivity among female intravenous drug users. Am J Public Health 1994; 84:382-7.
12. Powderly WG, Mayer KH. Centers for Disease Control and Prevention revised guidelines for human immunodeficiency virus (HIV) counseling, testing, and referral: targeting HIV specialists. Clin Infect Dis 2003; 37:813-9.
13. Naef MR, Bucher HC, Erb P, Gyr N, Bassetti S, Battegay M. Reduced infections with HIV and hepatitis A during a Swiss intravenous opiate maintenance program. J Acquir Immune Defic Syndr 1999; 21:349-51.